Author(s): Anuj Panchal, Anjali Khantal

Email(s): anujp1521@gmail.com

DOI: 10.52711/2321-5836.2024.00020   

Address: Anuj Panchal*, Anjali Khantal
Sri Aurobindo Institute of Pharmacy, Indore (453555), Madhya Pradesh, India.
*Corresponding Author

Published In:   Volume - 16,      Issue - 2,     Year - 2024


ABSTRACT:
One of the biggest issues facing the globe today is obesity. It primarily correlates with heart disease. Obesity can raise the risk of cardiovascular illness or muscle-related problems. Numerous fat tissues secrete bio-active cytokines, and these mediators affectglucose resistance, diabetes mellitus, hypertension, atherosclerosis, and heart attacks in addition to body weight homeostasis. Currently, there are three treatment options for obesity: pharmacological therapy, bariatric surgery, and lifestyle modification or non-pharmacotherapy (such as physical therapy, cognitive behavioral therapy, and healthy food planning). The market with the quickest rate of growth is pharmacotherapy. phentermine plus topiramate, Belviq, semaglutide, and naltrexone plus bupropion are among the medications used in pharmacological therapy.The Federal Drug Administration of the United States has authorized the first two drugs based on clinical studies that showed improvements in lipid profile, glucose resistance, and overweight. In this review, we will address the effectiveness of previous pharmacotherapy for obesity, with an emphasis on new therapeutic agents that enhance patient safety.


Cite this article:
Anuj Panchal, Anjali Khantal. A Review on Pharmacological and Non-Pharmacological Therapy for the treatment of Obesity with Cardiovascular Diseases. Research Journal of Pharmacology and Pharmacodynamics. 2024;16(2):114-8. doi: 10.52711/2321-5836.2024.00020

Cite(Electronic):
Anuj Panchal, Anjali Khantal. A Review on Pharmacological and Non-Pharmacological Therapy for the treatment of Obesity with Cardiovascular Diseases. Research Journal of Pharmacology and Pharmacodynamics. 2024;16(2):114-8. doi: 10.52711/2321-5836.2024.00020   Available on: https://rjppd.org/AbstractView.aspx?PID=2024-16-2-9


REFERENCES:
1.    Visco V, Izzo C, Bonadies D, et al. Interventions to Address Cardiovascular Risk in Obese Patients: Many Hands Make Light Work. J Cardiovasc Dev Dis. 2023; 10(8): 327.  
2.    S. Anuradha. Effect of Planned Teaching Programme regarding lifestyle modifications to prevent cardiovascular diseases among drivers at Sree Vidyanikethan Educational Trust (SVET), A. Rangampet-A.P. Int. J. Adv. Nur. Management. 2017; 5(3): 246-250.
3.    Sneha R. Dubey. A Descriptive Study to Assess the Knowledge of Adolescents regarding Obesity as a Predisposing Factor for Cardiovascular Diseases with A View to Develop an Educational Pamphlet in selected Urban Areas of Tumkur. International Journal of Advances in Nursing Management. 2021; 9(3): 319-1.
4.    Hina Kausar, Mohammed Ubaid-Ur-Rahaman. An Assessment Of Obesity Amongst Working Women. Research J. Pharmacology and Pharmacodynamics. 2013; 5(2): 134-135.
5.    Gupta RD, Tamanna N, Siddika N, Haider SS, Apu EH, Haider MR. Obesity and Abdominal Obesity in Indian Population: Findings from a Nationally Representative Study of 698,286 Participants. Epidemiologia (Basel). 2023; 4(2): 163-172.
6.    Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. E Clinical Medicine. 2023; 58: 101882.  
7.    Kosmalski M, Deska K, Bąk B, RóżyckaKosmalska M, Pietras T. Pharmacological Support for the Treatment of Obesity-Present and Future. Healthcare (Basel). 2023; 11(3): 433.  
8.    Ma H, Lin YH, Dai LZ, Lin CS, Huang Y, Liu SY. Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2023 Mar 7; 13(3): e061807.
9.    Hemlata Dewangan, Jhakeshwar Prasad, Trilochan Satapathy. Pancreatic Polypeptide: Biologically Active Neuropeptide and their Clinical Significance. Res. J. Pharmacology & Pharmacodynamics. 2016; 8(3): 211-218.
10.    Akram Ashames, Nageeb Hassan, Kristen Alamir, Kamar Modalaleh, Alin Naser, Aya Khawatmi. Correlation between Neck Circumference, Waist Circumference, Body Mass Index, and Overweight/Obesity among Ajman University Students. Research J. Pharm. and Tech. 2019; 12(5):2443-2452.
11.    Jindal A, Whaley-Connell A, Brietzke S, Sowers JR. Therapy of obese patients with cardiovascular disease. Curr Opin Pharmacol. 2013; 13(2): 200-204.
12.    Mittendorfer B, Peterson LR. Cardiovascular Consequences of Obesity and Targets for Treatment. Drug Discov Today Ther Strateg. 2008; 5(1): 53-61.
13.    Wijdan Rajh Hamza Al-Kraity, Murtadha M. Jawad. Comparison Visfatin level between Obese and Non Obese, Hypertensive and Normotensive patients with Ischemic Heart Disease. Research J. Pharm. and Tech. 2019; 12(7): 3547-3550.
14.    Kishan L. Jadhav, Priyanka R. Kapare, Divya V. Khairmode, Chaitali H. Keskar1, Farida Shaikh, Shradda Sawant, Akash S. Mali. Genetic Insights of Cholesterol and Atherosclerosis: Complex Biology. Asian J. Pharm. Res. 2018; 8(3): 175-184.
15.    Cunningham JW, Wiviott SD. Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit. Clin Cardiol. 2014; 37(11): 693-699.
16.    Jordan J, Astrup A, Engeli S, Narkiewicz K, Day WW, Finer N. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. J Hypertens. 2014; 32(6): 1178-1188.
17.    Nithyakala P, Sathyaprabha G, Venila J. Study on Efficacy of Topiramate: Impact on weight Loss in Obese patients. Research J. Pharm. and Tech. 2021; 14(3): 1565-1570.
18.    Dagli N, Kumar S, Ahmad R, Narwaria M, Haque M. An Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review. Cureus. 2023; 15(10): e46510.  
19.    Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022; 70(1): 5-13.
20.    Booth K, Clements JN. Role of Bupropion Plus Naltrexone for the Management of Obesity. J Pharm Technol. 2016;32(3):125-132.
21.    Sherman MM, Ungureanu S, Rey JA. Naltrexone/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management. 2016; 41(3): 164-172.
22.    Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014; 84: 1-11.
23.    Cesaro A, De Michele G, Fimiani F, et al. Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options. Front Cardiovasc Med. 2023; 10: 1187735.   
24.    Khera R, Pandey A, Chandar AK, et al. Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis. Gastroenterology. 2018; 154(5): 1309-1319.
25.    Jeon E, Lee KY, Kim KK. Approved AntiObesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon. J Obes Metab Syndr. 2023; 32(2): 106-120.
26.    Higuera-Hernández MF, Reyes-Cuapio E, Gutiérrez-Mendoza M, et al. Fighting obesity: Non-pharmacological interventions. Clin Nutr ESPEN. 2018; 25: 50-55.
27.    Foster-Schubert KE, McTiernan A, Frayo RS, et al. Human plasma ghrelin levels increase during a one-year exercise program. J Clin Endocrinol Metab. 2005; 90(2): 820-825.
28.    Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol. 2020; 75(2): 235-25.
29.    Greenberg I, Chan S, Blackburn GL. Nonpharmacologic and pharmacologic management of weight gain. J Clin Psychiatry. 1999; 60 Suppl 21: 31-36.
30.    Fogelholm M, Kukkonen-Harjula K, Nenonen A, Pasanen M. Effects of walking training on weight maintenance after a verylow-energy diet in premenopausal obese women: a randomized controlled trial. Arch Intern Med. 2000; 160(14): 2177-2184.
31.    Hall KD, Kahan S. Maintenance of Lost Weight and Long-Term Management of Obesity. Med Clin North Am. 2018; 102(1): 183-197.
32.    Feng Y, Zhao Y, Liu J, et al. Consumption of Dairy Products and the Risk of Overweight or Obesity, Hypertension, and Type 2 Diabetes Mellitus: A Dose-Response Meta-Analysis and Systematic Review of Cohort Studies. Adv Nutr. 2022; 13(6): 2165-2179.
33.    Aathira Menon, Apthadevi, Roshni P R. Nutritional Deficiencies after Bariatric Surgery. Res. J. Pharmacology and Pharmacodynamics.2019; 11(3): 120-123.
34.    Hassapidou M, Vlassopoulos A, Kalliostra M, et al. European Association for the Study of Obesity Position Statement on Medical Nutrition Therapy for the Management of Overweight and Obesity in Adults Developed in Collaboration with the European Federation of the Associations of Dietitians. Obes Facts. 2023; 16(1): 11-28
35.    Bhargava Vyasa. Obesity in India – The Omnipresent Influence. Research J. Pharmacology and Pharmacodynamics. 2013; 5(4). 220-226.

Recomonded Articles:

Author(s): Syed Sagheer Ahmed, Chandra Prakash. K, Saba Tabassum, Noor Salma, Ahalya Devi. K H

DOI: 10.5958/2321-5836.2019.00003.X         Access: Open Access Read More

Author(s): Aswani P. S., Kshirod Kumar Ratha, Dighe Dattatray Pandurang, M. M. Rao, Remya Vijayan

DOI: 10.5958/2321-5836.2018.00008.3         Access: Open Access Read More

Author(s): Purnendu Panda, Banamali Das, DS Sahu, SK Meher, BK Das, MM Rao, GChD Naga Lakshmi.

DOI: 10.5958/2321-5836.2015.00011.7         Access: Open Access Read More

Author(s): Syed Shafeeq. R, Shekshavali. T, Syed Sulthan Ahamed. S N

DOI: 10.5958/2321-5836.2018.00026.5         Access: Open Access Read More

Author(s): Purnendu Panda, Indu.S, Banamali Das, G.C. Bhuyan, M.M. Rao

DOI: 10.52711/2321-5836.2022.00047         Access: Closed Access Read More

Author(s): Purnendu Panda, Banamali Das, DS Sahu, SK Meher, Das, GC Nanda.

DOI: Not Available         Access: Open Access Read More

Author(s): Shameer Pasha, Mohamed Khaleel, Sukhen Som.

DOI: Not Available         Access: Open Access Read More

Author(s): Chunendra Kumar, Shiv Shankar Shukla, Ravindra Kumar Pandey

DOI: 10.5958/2321-5836.2017.00016.7         Access: Open Access Read More

Author(s): Kishan K G, Shekshavali. T, Kuppast I.J, Kishan Kumar MA, Jeevanagouda Patil

DOI: 10.5958/2321-5836.2016.00030.6         Access: Open Access Read More

Author(s): T. Shekshavali, S. Roshan

DOI: 10.5958/2321-5836.2016.00031.8         Access: Open Access Read More

Author(s): M. Vanajakshi, J.H. Virupaksha, Shilpa Maria

DOI: 10.5958/2321-5836.2016.00033.1         Access: Open Access Read More

Author(s): Sudhanshu Kumar Meher, Purnendu Panda, Banmali Das, G. C. Bhuyan, Dr. K. K. Rath

DOI: 10.5958/2321-5836.2018.00023.X         Access: Open Access Read More

Author(s): K. Rashid, C. Senthil Kumar, P. M. Mohammed Haleel

DOI: 10.5958/2321-5836.2017.00037.4         Access: Open Access Read More

Author(s): Sudhanshu Kumar Meher, Banmali Das, Purnendu Panda, GC Bhuyan, MM Rao.

DOI: 10.5958/2321-5836.2016.00006.9         Access: Open Access Read More

Author(s): Nikhil P. Varghese, Shekshavali T. , Prathib B., I.J. Kuppast

DOI: 10.5958/2321-5836.2017.00007.6         Access: Open Access Read More

Author(s): Jeevanagouda Patil, Kuppast I.J, Kishan Kumar M A, Kishan K G

DOI: 10.5958/2321-5836.2016.00032.X         Access: Open Access Read More

Author(s): Manasa K.S, Kuppast I.J, Kishan Kumar M.A , Akshara K

DOI: 10.5958/2321-5836.2016.00034.3         Access: Open Access Read More

Author(s): Madhavi Sahu, S. Prakash Rao

DOI: 10.5958/2321-5836.2018.00031.9         Access: Open Access Read More

Author(s): Sachin Aglawe, Amol Gayke, Kavita Sharma, Sonali Jadhav, Sanjivani Gore, Bhagyashri Pandit, Sonali Valate, Mayuri Wagh

DOI: 10.5958/2321-5836.2020.00003.8         Access: Open Access Read More

Author(s): Sanjib Kumar Das, Anuradha Das, Banamali Das, Purnendu Panda, G. C. Bhuyan, Bipin Bihari Khuntia

DOI: 10.5958/2321-5836.2017.00036.2         Access: Open Access Read More


Recent Articles




Tags